Evidence map›Paper›PMID 33008934›Full record

Trial reportThe European respiratory journal2021

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.

Toby M Maher, Ulrich Costabel, Marilyn K Glassberg, Yasuhiro Kondoh, Takashi Ogura, Mary Beth Scholand, David Kardatzke, Monet Howard, Julie Olsson, Margaret Neighbors and 2 more

Open access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Immunological mechanisms and therapeutic approaches in pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Toby M MaherNIHR Respiratory Clinical Research Facility, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK.
Ulrich CostabelRuhrlandklinik, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-2804-9511
Marilyn K GlassbergUniversity of Arizona, College of Medicine, Phoenix, AZ, USA.ORCID 0000-0003-1990-6614
Yasuhiro KondohTosei General Hospital, Aichi, Japan.
Takashi OguraKanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Mary Beth ScholandUniversity of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-6513-8893
David KardatzkeGenentech, Inc., South San Francisco, CA, USA.
Monet HowardGenentech, Inc., South San Francisco, CA, USA.
Julie OlssonGenentech, Inc., South San Francisco, CA, USA.
Margaret NeighborsGenentech, Inc., South San Francisco, CA, USA.
Paula BelloniGenentech, Inc., South San Francisco, CA, USA.
Jeffrey J SwigrisNational Jewish Health, Denver, CO, USA.
Kanagawa Cardiovascular and Respiratory Center · JPNational Jewish Health · USRoyal Brompton Hospital · GBRuhrlandklinik · DETosei General Hospital · JPUniversity of Arizona · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF).Patients with IPF aged ≥40 years with forced vital capacity (FVC) of 40%-100% predicted and diffusing capacity for carbon monoxide of 25%-90% predicted and who were treatment-naïve (cohort A) or receiving pirfenidone (2403 mg·day

Indexed as

Antibodies, MonoclonalIdiopathic Pulmonary FibrosisAnti-Inflammatory Agents, Non-SteroidalHumansInterleukin-13PyridonesTreatment OutcomeVital CapacityAntibodies, MonoclonalAnti-Inflammatory Agents, Non-SteroidalInterleukin-13lebrikizumabPyridones

Identifiers

PMID33008934
PMCPMC7859504
OpenAlexW3090728996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.